VA
REGN icon

Verdad Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Verdad Advisers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-283
Closed -$219K – 259
2026
Q1 		$219K Buy
+283
New +$217K 0.25% 126
2024
Q3 		$676K Sell
643
-697
-52% -$776K 0.9% 39
2024
Q2 		$1.41M Buy
1,340
+81
+6% +$78.5K 1.63% 12
2024
Q1 		$1.21M Buy
+1,259
New +$1.2M 1.32% 14

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Verdad Advisers's REGN Position: Q2 2026 in Review

Verdad Advisers sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 283 shares — an estimated $219K sold.

Verdad Advisers first reported a position in REGN in Q1 2024 and held it in 4 quarters. The position peaked at $1.41M in Q2 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Verdad Advisers reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Verdad Advisers sold 283 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $219K.
  • Verdad Advisers first reported a position in Regeneron Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Verdad Advisers's Regeneron Pharmaceuticals position peaked at $1.41M in Q2 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.